PDS Biotechnology (NASDAQ: PDSB – Get Assessment) Its price target was reduced by Alliance Global Partners from $ 18.00 to $ 16.00 in a research report sent to investors on Friday, The Fly reports.
Numerous other equity research analysts have also published reports on the stock. Noble Financial reissued a buy rating and issued a $ 22.00 price target on shares of PDS Biotechnology in a report Thursday. StockNews.com raised shares of PDS Biotechnology to a sell rating in a report on Saturday, April 9. Finally, in a report on Friday, Zacks Investment Research downgraded shares of PDS Biotechnology from a hold rating to a sell rating. Two investment analysts rated the stock with a sell rating and six rated the stock buy. According to MarketBeat, PDS Biotechnology has a Consensus Consensus Rating and a Consensus Target Price of $ 17.00.
NASDAQ: PDSB is trading higher by $ 0.73 during trading hours on Friday, reaching $ 4.56. The company’s shares had a trading volume of 552,690 shares, compared to its average volume of 232,316. The company has a 50-day simple moving average of $ 5.66 and a 200-day simple moving average of $ 7.26. PDS Biotechnology has a 1-year low of $ 3.47 and a 1-year high of $ 17.85.
PDS Biotechnology (NASDAQ: PDSB – Get Rating) last released its earnings results on Wednesday, May 11. The company posted ($ 0.32) EPS for the quarter, missing analyst consensus estimates of ($ 0.23) of ($ 0.09). In the same period last year, the company posted ($ 0.14) EPS. Sell-side analysts expect PDS Biotechnology to post EPS -0.98 for the current year.
Several institutional investors and hedge funds have recently made changes to their positions in PDSB. Bank of America Corp DE increased its stake in PDS Biotechnology shares by 7,093.1% during the fourth quarter. Bank of America Corp DE now owns 4,172 shares in the company worth $ 34,000 after buying another 4,114 shares in the last quarter. UBS Group AG acquired a new equity interest in PDS Biotechnology during the third quarter valued at approximately $ 44,000. Minot Wealth Management LLC acquired a new equity interest in PDS Biotechnology during the first quarter valued at approximately $ 62,000. Andesa Financial Management Inc. acquired a new position in PDS Biotechnology during the first quarter worth approximately $ 77,000. Finally, GSA Capital Partners LLP purchased a new position in PDS Biotechnology during the first quarter valued at approximately $ 89,000. 20.94% of the stock is currently held by hedge funds and other institutional investors.
Information on PDS biotechnology (Get evaluation)
PDS Biotechnology Corporation, a clinical stage biopharmaceutical company, focuses on the development of multifunctional anticancer immunotherapies. Its flagship product is PDS0101 (HPV16), which is in a Phase II clinical trial providing first-line treatment for recurrent / metastatic head and neck cancer, human papillomavirus-associated malignancies, and cancer of the cervix.
Receive news and assessments for PDS biotechnology every day – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Biotech PDS and related companies with MarketBeat.com’s FREE daily newsletter.